Brokerages Set OrthoPediatrics Corp. (NASDAQ:KIDS) Price Target at $24.44

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) have been assigned an average rating of “Moderate Buy” from the eleven brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $24.4444.

KIDS has been the subject of several research analyst reports. BTIG Research reiterated a “buy” rating and issued a $24.00 price objective on shares of OrthoPediatrics in a research report on Friday, May 1st. Truist Financial set a $17.00 price objective on OrthoPediatrics in a research report on Friday, May 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Tuesday, April 21st. Canaccord Genuity Group set a $25.00 price objective on OrthoPediatrics in a research report on Friday, April 24th. Finally, Wall Street Zen upgraded OrthoPediatrics from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th.

Insider Activity

In other OrthoPediatrics news, CEO David R. Bailey sold 19,535 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $17.25, for a total transaction of $336,978.75. Following the completion of the transaction, the chief executive officer owned 298,020 shares of the company’s stock, valued at $5,140,845. This represents a 6.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Gregory A. Odle sold 8,433 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $17.25, for a total value of $145,469.25. Following the transaction, the insider directly owned 187,735 shares of the company’s stock, valued at approximately $3,238,428.75. This trade represents a 4.30% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 58,171 shares of company stock worth $1,003,450. 32.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On OrthoPediatrics

Large investors have recently bought and sold shares of the company. Prosight Management LP boosted its position in OrthoPediatrics by 319.2% during the 3rd quarter. Prosight Management LP now owns 308,707 shares of the company’s stock worth $5,720,000 after acquiring an additional 235,060 shares during the last quarter. Inceptionr LLC acquired a new position in OrthoPediatrics during the 3rd quarter worth approximately $265,000. Triodos Investment Management BV boosted its position in OrthoPediatrics by 17.8% during the 3rd quarter. Triodos Investment Management BV now owns 132,500 shares of the company’s stock worth $2,454,000 after acquiring an additional 20,000 shares during the last quarter. Granahan Investment Management LLC boosted its position in OrthoPediatrics by 35.1% during the 1st quarter. Granahan Investment Management LLC now owns 896,741 shares of the company’s stock worth $14,231,000 after acquiring an additional 232,760 shares during the last quarter. Finally, Sei Investments Co. boosted its position in OrthoPediatrics by 31.1% during the 1st quarter. Sei Investments Co. now owns 82,081 shares of the company’s stock worth $1,303,000 after acquiring an additional 19,489 shares during the last quarter. Institutional investors and hedge funds own 69.05% of the company’s stock.

OrthoPediatrics Price Performance

Shares of KIDS opened at $18.37 on Monday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.37 and a current ratio of 5.21. The stock has a 50 day simple moving average of $16.72 and a 200 day simple moving average of $17.34. OrthoPediatrics has a 52-week low of $14.42 and a 52-week high of $23.70. The firm has a market capitalization of $471.74 million, a PE ratio of -10.93 and a beta of 0.99.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.04. OrthoPediatrics had a negative return on equity of 7.01% and a negative net margin of 16.31%.The business had revenue of $59.36 million during the quarter, compared to analyst estimates of $58.29 million. Sell-side analysts predict that OrthoPediatrics will post -1.13 EPS for the current fiscal year.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.